Washington: A Florida Atlantic University researcher has published a review for clinicians on the optimal utilization of aspirin to treat and prevent heart attacks as well as commentary on the cholesterol lowering drugs to prevent colorectal and other cancers.Charles H. Hennekens, M.D., Dr.P.H., the first Sir Richard Doll professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at the University and James E. Dalen, M.D., M.P.H., dean emeritus, University of Arizona College of Medicine and executive director of the Weil Foundation published this update in the current issue of the American Journal of Medicine.In a commentary published in Clinical Investigation, Hennekens and David J. Bjorkman, M.D., M.S.P.H., dean and executive director of medical affairs for the Charles E. Schmidt College of Medicine consider the emerging evidence on aspirin in the prevention of colorectal and other cancers and provide advice to doctors."All patients suffering from blockage of an artery in the heart or brain should receive 325 mg regular aspirin promptly and daily aspirin thereafter to reduce their death rate as well as subsequent heart attacks and strokes," said Hennekens.In addition, he also stressed that "among long-term survivors of prior heart attacks, occlusive strokes or blockages in the arteries of the legs, aspirin should be continued long-term unless there is a specific contraindication."Hennekens and Bjorkman advise doctors that, based on the current totality of evidence, in the primary prevention of vascular disease and cancer, any judgments about prescribing long-term aspirin therapy for apparently healthy individuals should be based on individual clinical judgments between the doctor and each of his or her patients.
UPSC exam row: Students continue protests
Salman Khan`s Kick hits the screen
ISIS orders female genital mutilation in Iraq
Complete trial against corrupt MPs within a year: PM Modi